TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.52
−1.05%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.34
- Revenue estimate
- $3.3M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.37
- EPS estimate
- -$0.32
- Revenue actual
- —
- Revenue estimate
- $1.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +298.1%
- Revenue beats (12Q)
- 2
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $52
- PT range
- $35 – $69
- Analysts
- 7
7 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026